Research Topics
| Joshua T SchifferSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
|
Detail Information
Publications
New concepts in understanding genital herpesJoshua T Schiffer
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Institute and Program in Infectious Diseases, 1616 Eastlake Avenue, LE 500, Seattle, WA 98102, USA
Curr Infect Dis Rep 11:457-64. 2009..This fact highlights the importance of laboratory diagnostics for this lifelong infection, and the need for an HSV vaccine...
Rapid host immune response and viral dynamics in herpes simplex virus-2 infectionJoshua T Schiffer
Department of Medicine, University of Washington, Seattle, Washington, USA
Nat Med 19:280-90. 2013..The fact that immune responses usually control viral replication in genital skin before lesions develop provides hope that enhancing such responses could lead to effective vaccines and immunotherapies...- Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapyJoshua T Schiffer
Department of Medicine, University of Washington, Seattle, WA 98102, USA
J Antimicrob Chemother 66:2593-600. 2011..We sought to describe the impact of twice-daily aciclovir and famciclovir on shedding episodes... - Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantationJoshua T Schiffer
Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA
Haematologica 94:1101-8. 2009.... - Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical modelJoshua T Schiffer
Department of Medicine, University of Washington, Seattle, WA 98195, USA
Sci Transl Med 1:7ra16. 2009..Frequent HSV-2 shedding episodes in humans are explained by nearly constant release of small numbers of viruses from neurons that terminate in the genital tract... - Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodesJoshua T Schiffer
Department of Medicine, Laboratory Medicine, Global Health Medicine, University of Washington, Seattle, WA 98195, USA
Proc Natl Acad Sci U S A 107:18973-8. 2010..The model suggests that the rate of containment of infected cells by the peripheral mucosal immune system is the major driver of duration and severity of HSV-2 reactivation in the immunocompetent host... - The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactionsJoshua T Schiffer
Department of Medicine, University of Washington, Seattle, Washington, USA
J Infect Dis 204:554-61. 2011..Herpes simplex virus type 2 (HSV-2) reactivations in the genital tract are responsible for mucocutaneous lesions and transmission and manifest as discrete shedding episodes... - Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trialsChristine Johnston
Department of Medicine, University of Washington, Seattle, WA 98104, USA
Lancet 379:641-7. 2012..Skin and mucosal herpes simplex virus type 2 (HSV-2) shedding predominantly occurs in short subclinical episodes. We assessed whether standard-dose or high-dose antiviral therapy reduces the frequency of such shedding... - Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpesNicholas J Moss
Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA
J Virol 86:9952-63. 2012..These data suggest that other immune cell subsets with alternate phenotypes or anatomical locations may be responsible for genital herpes control in chronically infected individuals... - Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tractJoshua T Schiffer
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States Department of Medicine, University of Washington, Seattle, United States
elife 2:e00288. 2013..We conclude that HSV-2 infection is characterized by extremely rapid virological growth and containment at multiple contemporaneous sites within genital epithelium. DOI:http://dx.doi.org/10.7554/eLife.00288.001... - Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2Ramzi A Alsallaq
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Sex Transm Dis 37:290-7. 2010..The continuation of developing Herpes simplex virus type-2 (HSV-2) prophylactic vaccines requires parallel mathematical modeling to quantify the effect on the population of these vaccines... - Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapyJeffrey Thomas Schouten
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Acquir Immune Defic Syndr 60:68-71. 2012..Though HIV-1 viral load was 0.19 logs higher in HSV-2-positive versus HSV-2-negative persons, first and second phase clearance rates during antiretroviral therapy were equal between participants in these 2 groups... - CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistenceLichen Jing
Department of Medicine, University of Washington, Seattle, Washington, USA
J Virol 87:2617-27. 2013..We conclude that human memory CD4 T-cell responses show a pattern of pronounced immunodominance for both chronic and self-limited viral infections and that this pattern can persist over several decades in the absence of antigen... - Targeted DNA mutagenesis for the cure of chronic viral infectionsJoshua T Schiffer
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA
J Virol 86:8920-36. 2012..We then review issues regarding persistence of HIV-1, HBV, and HSV that are relevant to eradication with genome-altering approaches... 
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysisJoshua T Schiffer
Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA
J Acquir Immune Defic Syndr 44:229-34. 2007..6%. These results support early initiation of HAART in patients with AIDS, except when IRIS-related mortality rates are high...